Long-term outcomes of 1,263 patients with mycosis fungoides and Sézary syndrome from 1982 to 2009.
about
Systemic therapy for cutaneous T-cell lymphoma: who, when, what, and why?T-cell Lymphoma Epidemiology: the Known and Unknown.Mycosis fungoides and Sézary syndrome: Current challenges in assessment, management and prognostic markers.Increased Levels of Plasma Epstein Barr Virus DNA Identify a Poor-Risk Subset of Patients With Advanced Stage Cutaneous T-Cell LymphomaGenetic markers associated with progression in early mycosis fungoides.Staphylococcal enterotoxins stimulate lymphoma-associated immune dysregulation.Medical history, lifestyle, family history, and occupational risk factors for mycosis fungoides and Sézary syndrome: the InterLymph Non-Hodgkin Lymphoma Subtypes Project.Cutaneous T-Cell Lymphoma: A Review with a Focus on Targeted Agents.Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma.Resimmune, an anti-CD3ε recombinant immunotoxin, induces durable remissions in patients with cutaneous T-cell lymphoma.Identification of geographic clustering and regions spared by cutaneous T-cell lymphoma in Texas using 2 distinct cancer registriesThe Use of Transcriptional Profiling to Improve Personalized Diagnosis and Management of Cutaneous T-cell Lymphoma (CTCL).Rapidly progressive stage IVB mycosis fungoides treated with low-dose total skin electron beam therapyDemographic patterns of cutaneous T-cell lymphoma incidence in Texas based on two different cancer registriesClinically significant responses achieved with romidepsin across disease compartments in patients with cutaneous T-cell lymphomaResults of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis.Genomic profiling of Sézary syndrome identifies alterations of key T cell signaling and differentiation genesAllogeneic stem-cell transplantation in patients with cutaneous lymphoma: updated results from a single institutionCD30+ Cutaneous T Cell Lymphoma: Response to Rotational Total Skin Electron Irradiation.TH2 cytokines from malignant cells suppress TH1 responses and enforce a global TH2 bias in leukemic cutaneous T-cell lymphoma.Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model.Elucidating the role of interleukin-17F in cutaneous T-cell lymphomaPrognostic factors, prognostic indices and staging in mycosis fungoides and Sézary syndrome: where are we now?Responses to romidepsin in patients with cutaneous T-cell lymphoma and prior treatment with systemic chemotherapy.Brentuximab vedotin in CD30(+) primary cutaneous T-cell lymphomas: a review and analysis of existing data.Multidisciplinary Management of Mycosis Fungoides/Sézary Syndrome.Clinical manifestations and pathogenesis of cutaneous lymphomas: current status and future directions.Sézary Syndrome: Clinical and Biological Aspects.Targeting histone deacetylases in T-cell lymphoma.Gene expression analysis in Cutaneous T-Cell Lymphomas (CTCL) highlights disease heterogeneity and potential diagnostic and prognostic indicators.Folliculotropic mycosis fungoides: clinical and epidemiological evaluation in a single center in Brazil.TruSeq-Based Gene Expression Analysis of Formalin-Fixed Paraffin-Embedded (FFPE) Cutaneous T-Cell Lymphoma Samples: Subgroup Analysis Results and Elucidation of Biases from FFPE Sample Processing on the TruSeq Platform.Connecting the dots in cutaneous T cell lymphoma (CTCL): STAT5 regulates malignant T cell proliferation via miR-155.Minimal residual disease monitoring with high-throughput sequencing of T cell receptors in cutaneous T cell lymphoma.Prognostic factors and risk stratification in early mycosis fungoides.Are we close to a prognostic index for cutaneous T cell lymphoma?Results from a Phase I/II Open-Label, Dose-Finding Study of Pralatrexate and Oral Bexarotene in Patients with Relapsed/Refractory Cutaneous T-cell Lymphoma.Low-dose total skin electron beam therapy for cutaneous lymphoma : Minimal risk of acute toxicities.Validation of cutaneous lymphoma international prognostic index (CLIPI) for mycosis fungoides and Sézary syndrome.Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium.
P2860
Q30239965-6B073A8D-2DEF-4C7C-9CA8-70778E8E1BE2Q30239985-FE5B7C5E-812A-4C0E-B86F-EEDB100ACF92Q30252152-3972E766-A43E-4109-A1EE-DA35707B7D87Q30276132-B674D527-360F-4E12-AD9D-418BF834FCEBQ33556038-2B350841-193A-4FD4-8FF1-815D02466D4EQ33987080-17946CA3-9701-408D-BBB9-1819A8D271A4Q34137936-FFB35A84-095A-4AE9-B8A4-58D15BA41F3DQ34516083-2B3EECCA-1AA9-4B8A-9CBC-23E5161A000CQ35222112-B7CBB5A5-B73A-4CBA-846C-E0079675897BQ35669880-59FB5A28-7247-4307-B1D5-7B3798C5A3D1Q35689166-2EC173B4-4BFD-4C01-B28D-67456307AD8EQ35752062-597A466B-7928-4929-BDC6-2DD0FE071057Q35825986-6EDF181D-5B5C-4037-BA1F-8B6C34B02DA7Q36051812-AEFA1A08-39A1-4CA9-9B3B-F8BB0B785789Q36519044-3F824544-EA9E-489D-82DE-9EA65E3B6D46Q36534677-0456B63A-DF1F-4BE7-A7CB-0F1946756E12Q36793430-712D0CB0-27A7-49C0-A341-8312367320A0Q36865042-FFC488BE-9228-487F-8F0E-E5D526C550C4Q36999986-E67F5C4B-BDE9-430A-91D7-654E3FCAD720Q37025122-6989F9AC-6206-4F9C-BF78-1F1FF7B4A98AQ37163606-A1AA1D8D-27C9-41DE-BCA8-A8149B8A7404Q37216178-DE96FAAA-0F72-4F8D-AD76-C97DABB9B31EQ38196931-FE9DFA39-321A-45EB-A7CA-FC39F6EF58D2Q38602496-EB3DB9A5-06BD-4D2D-9B04-64ACE5124F6EQ38649847-F9C61F49-EEA9-4429-94E2-546104A740A4Q38765889-DBBD9F9F-B8AB-46E8-AD78-53E01938FE7CQ38805440-6B848709-3EBF-4946-A1C1-6A742F73F469Q38814744-AAF298A4-766A-4EE0-AFAB-799D284896C7Q38998630-AFE0FCA8-58FE-4D5A-A77C-9C5D5D62FBB4Q40150337-A0198416-AE3D-4056-8709-B87CCAEC8C24Q40164145-D7885EF0-712B-4F25-B262-09C8A436A84FQ42270898-2D8D39C4-572E-411D-BF51-A93DBD24245EQ42574067-FC0D9064-F3EF-4A92-B302-CE07EAFB7F76Q43444250-F1C172C4-4ECE-4975-9110-389D181A3E8AQ43680684-470B9446-9372-425F-BC99-2A91E6E5E2A3Q44382232-8DA6C1A3-524E-427E-A3E0-5263FB730DA0Q46006814-715F5646-81AF-45B9-808E-0C478A5A94FDQ47302497-EE89AC95-2C85-4402-B62A-91B531F7D467Q47818116-6CEDD616-5D43-4075-B22B-625ED41795B1Q47898250-26F6D0B2-E554-4366-A8AA-66AC03AB7708
P2860
Long-term outcomes of 1,263 patients with mycosis fungoides and Sézary syndrome from 1982 to 2009.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 31 July 2012
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Long-term outcomes of 1,263 pa ...... ry syndrome from 1982 to 2009.
@en
Long-term outcomes of 1,263 pa ...... ry syndrome from 1982 to 2009.
@nl
type
label
Long-term outcomes of 1,263 pa ...... ry syndrome from 1982 to 2009.
@en
Long-term outcomes of 1,263 pa ...... ry syndrome from 1982 to 2009.
@nl
prefLabel
Long-term outcomes of 1,263 pa ...... ry syndrome from 1982 to 2009.
@en
Long-term outcomes of 1,263 pa ...... ry syndrome from 1982 to 2009.
@nl
P2093
P2860
P1476
Long-term outcomes of 1,263 pa ...... ry syndrome from 1982 to 2009.
@en
P2093
Lotika Singh
Madeleine Duvic
Rakhshandra Talpur
Sarah Seyfer
Seema Daulat
Tanya Trynosky
P2860
P304
P356
10.1158/1078-0432.CCR-12-0604
P407
P577
2012-07-31T00:00:00Z